Infinity Pharma stock gains 24% on survival analysis data for a phase 2 trial, Q2 results

Retrieved on: 2022-08-11 03:09:48

Tags for this article:

Click the tags to see associated articles and topics

Infinity Pharma stock gains 24% on survival analysis data for a phase 2 trial, Q2 results. View article details on hiswai:

Excerpt

Shares of micro-cap clinical-stage biotech Infinity Pharmaceuticals (INFI) jumped 24.3% to $0.92 in Wednesday mid-day trading, after it announced ...

Article found on: seekingalpha.com